Arrowhead Pharmaceuticals (ARWR) Operating Income (2010 - 2026)

Arrowhead Pharmaceuticals (ARWR) has 17 years of Operating Income data on file, last reported at -$141.3 million in Q1 2026.

• Quarterly Operating Income fell 137.06% year-over-year to -$141.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$221.9 million (down 87.17% YoY) and the FY2025 annual result came in at $98.3 million, up 116.36% from the prior year.
• Operating Income eased to -$141.3 million in Q1 2026, from $40.8 million in the prior quarter.
• In the past five years, Operating Income ranged from a high of $381.2 million in Q1 2025 to a low of -$176.1 million in Q2 2024.
• A 5-year average of -$54.3 million and a median of -$102.7 million in 2023 frame the typical range for Operating Income.
• Annual changes were most pronounced in 2024 — Operating Income sank 362.0% — and 2025, when it soared 402.08%.
• Tracing ARWR's Operating Income over 5 years: stood at -$42.1 million in 2022, then tumbled by 224.07% to -$136.5 million in 2023, then fell by 18.21% to -$161.4 million in 2024, then jumped by 125.28% to $40.8 million in 2025, then plunged by 446.15% to -$141.3 million in 2026.
• The last three Operating Income figures came in at -$141.3 million (Q1 2026), $40.8 million (Q4 2025), and $44.1 million (Q3 2025), per Business Quant data.